Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ACCL vs SBC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SBC Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 8–2 Matrix Metrics)

SBC Overall Winner 6-Pillar Tally: ACCL 1 – 4 SBC (1 Tie) Matrix Metrics: ACCL 2 – 8 SBC

As of Nov 16, 2026, SBC Medical Group Holdings Incorporated (SBC) is the stronger overall head-to-head candidate over ACCL (ACCL) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACCL carries a Unified Composite Score of 63.4/100 (BUY) at $2.36 (N/M Forward P/E, 4.5% operating margin), whereas SBC carries 47.6/100 (HOLD) at $6.42 (13.6x Forward P/E, 37.3% operating margin).

  • Composite vs. Pillar Nuance: While ACCL currently prints a higher short-term Unified Composite Score (63.4/100 BUY vs. SBC 47.6/100 HOLD), SBC captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (37.3% vs. 4.5% operating margin) and revenue trajectory (+13.4% vs. +11.3% YoY).
  • Technical & Structure Timing Caution: ACCL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.2); meanwhile SBC trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 63.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ACCL vs SBC
ACCL US Equity
ACCL
Institutional Equity
$2.36
-0.84% 1D
Market Cap $33.5M
TTM Revenue $5.2M
Forward P/E N/M
Beta / 30D Vol -0.20β · 60% Vol
Unified Composite Score
63.4 / 100 BUY
Tech 68.0 Fund 58.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.9%), weak momentum, RSI 39
RSI-14: 39.2 · SMA20: $2.54 · SMA50: $2.65
SBC NASDAQ Head-to-Head Winner
SBC Medical Group Holdings Incorporated Common Stock
Services-Offices & Clinics Of Doctors Of Medicine
$6.42
-12.65% 1D
Market Cap $549.2M
TTM Revenue $175M
Forward P/E 13.6x
Beta / 30D Vol 0.65β · 150% Vol
Unified Composite Score
47.6 / 100 HOLD
Tech 15.0 Fund 39.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (14.7% over 20 days), RSI 63
RSI-14: 63.4 · SMA20: $5.49 · SMA50: $5.17

6-Pillar Scorecard Institutional Category Breakdown (ACCL 1 – 4 SBC)

Columns: Metric · ACCL · SBC
1. Valuation Multiples SBC
Forward P/E N/M 13.6x
Trailing P/E 120.0x 11.4x
PEG Ratio N/M 2.02x
EV / Revenue 6.5x 3.1x
2. Growth & Scale SBC
Revenue Growth (YoY) +11.3% +13.4%
Earnings Growth (YoY) -62.5% +338.9%
TTM Revenue (USD) $5.2M $175M
Market Cap $33.5M $549.2M
3. Profitability & Quality SBC
Gross Margin 42.4% 71.9%
Operating Margin 4.5% 37.3%
Net Profit Margin 5.5% 28.0%
Return on Equity (ROE) 7.0% 18.9%
4. Balance Sheet & Cash Flow SBC
Cash Generation (TTM) $245,425 EBITDA $69M EBITDA
Cash Flow Margin 4.7% EBITDA Mgn 39.2% EBITDA Mgn
Net Cash / Leverage $0.43 Book/Sh · 7.0% ROE $2.57 Book/Sh · 18.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat ACCL
OpEx & R&D Intensity 37.9% of Rev ($2.0M) 34.6% of Rev ($61M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Consulting Services Operator Consulting Services Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ACCL (2) vs SBC (8)
Institutional Metric ACCL SBC Criterion Row Edge
Market Capitalization
Scale
$33.5M $549.2M Larger Scale SBC
Trailing P/E Ratio
Valuation
120.0x 11.4x Lower Multiple SBC
Forward P/E Ratio
Valuation
N/M 13.6x Lower Multiple SBC
Revenue Growth (YoY)
Growth
+11.3% +13.4% Higher Growth SBC
Operating Margin (TTM)
Profitability
4.5% 37.3% Higher Margin SBC
Net Profit Margin
Profitability
5.5% 28.0% Higher Margin SBC
Return on Equity (ROE)
Capital Efficiency
7.0% 18.9% Higher ROE SBC
52-Week Range Position
Momentum
30% ($1–$5) 79% ($3–$7) Stronger Trend SBC
Beta / 30D Volatility
Risk Regime
-0.20β · 60% Vol 0.65β · 150% Vol Lower Realized Risk ACCL
Unified Institutional Score
Composite Signal
63.4 / 100 (BUY) 47.6 / 100 (HOLD) Higher Composite ACCL
Trailing 12M Revenue (USD)
Operating Scale
$5.2M $175M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
42.4% 71.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.5x EV/Rev 2.02x PEG · 3.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$245,425 EBITDA ($0.43 Book/Sh · 7.0% ROE) $69M EBITDA ($2.57 Book/Sh · 18.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SBC +35.01 pp
ACCL: -12.26% · SBC: +22.75%
3M Horizon SBC +92.31 pp
ACCL: -16.9% · SBC: +75.41%
6M Horizon SBC +54.89 pp
ACCL: +60.55% · SBC: +115.44%
1Y Horizon SBC +134.74 pp
ACCL: -43.67% · SBC: +91.07%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACCL vs SBC. Trailing 12-month operating profitability (ACCL 4.5% vs SBC 37.3%) and valuation multiples (ACCL N/M vs SBC 13.6x Forward P/E) are benchmarked directly in Pillar 4 below.

ACCL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.2M
Gross Margin42.4%
Op. Margin4.5%
ROE / Fwd P/E7.0% · N/M
SBC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$175M
Gross Margin71.9%
Op. Margin37.3%
ROE / Fwd P/E18.9% · 13.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ACCL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ACCL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SBC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SBC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ACCL Moat Profile Cyclical / Execution-Driven Positioning
Consulting Services Operator
Competes within the Consulting Services value chain with $33.5M market capitalization and 4.5% operating margin.
OpEx & R&D Reinvestment 37.9% of Rev ($2.0M)
90D Engineering Disclosures 0 Published
SBC Moat Profile High-Margin Pricing Power Moat
Consulting Services Operator
Competes within the Consulting Services value chain with $549.2M market capitalization and 37.3% operating margin.
OpEx & R&D Reinvestment 34.6% of Rev ($61M)
90D Engineering Disclosures 0 Published

Investor FAQ ACCL vs SBC Key Questions & Quantitative Answers

As of Nov 16, 2026, SBC Medical Group Holdings Incorporated (SBC) is the stronger overall head-to-head candidate over ACCL (ACCL) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ACCL carries a Unified Composite Score of 63.4/100 (BUY) at $2.36 (N/M Forward P/E, 4.5% operating margin), whereas SBC carries 47.6/100 (HOLD) at $6.42 (13.6x Forward P/E, 37.3% operating margin). Composite vs. Pillar Nuance: While ACCL currently prints a higher short-term Unified Composite Score (63.4/100 BUY vs. SBC 47.6/100 HOLD), SBC captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (37.3% vs. 4.5% operating margin) and revenue trajectory (+13.4% vs. +11.3% YoY). Technical & Structure Timing Caution: ACCL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.2); meanwhile SBC trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 63.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SBC leads the Growth & Scale pillar: ACCL posts +11.3% YoY revenue growth and -62.5% YoY earnings growth on $5.2M TTM revenue (42.4% gross margin, 4.5% operating margin), compared with SBC at +13.4% YoY revenue growth and +338.9% YoY earnings growth on $175M TTM revenue (71.9% gross margin, 37.3% operating margin). On trailing 12-month operating scale, ACCL generates $5.2M in USD-normalized revenue versus $175M for SBC. In operating R&D and SG&A reinvestment, ACCL deploys 37.9% of Rev ($2.0M) (0 90-day corporate R&D disclosures) versus 34.6% of Rev ($61M) (0 disclosures) for SBC.

SBC screens cheaper on headline valuation multiples. ACCL trades at N/M Forward P/E, 120.0x Trailing P/E, N/M PEG, and 6.5x EV/Revenue (4.7% EBITDA margin), whereas SBC trades at 13.6x Forward P/E, 11.4x Trailing P/E, 2.02x PEG, and 3.1x EV/Revenue (39.2% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACCL (7.0% ROE) versus SBC (18.9% ROE) capital efficiency.

In options market volatility and institutional positioning, ACCL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.20β · 60% Vol realized risk). By comparison, SBC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 150% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.